Use this button to switch between dark and light mode.

Exclusive! Marketing Exclusivities for Prescription Drugs

March 26, 2024 (1 min read)

Understand the parameters of non-patent marketing exclusivities for prescription drugs in the United States.

Read now »

Related Content

  • Hatch-Waxman Safe Harbor Checklist
    Refer to this checklist when advising pharmaceutical companies about conducting research studies required for FDA approval of a generic drug.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.

  • Explore the Practical Guidance Journal Spring 2024 Edition, featuring guidance on protecting attorney-client privilege and work product in a generative AI world, using AI to manage the attorney client relationship, an overview of privacy regulations in the United States, and a primer on the new Corporate Transparency Act requirements.
  • Generative Artificial Intelligence (AI) Resource Kit is a frequently updated collection of current Practical Guidance materials on generative AI, ChatGPT, and similar tools.
  • Listen Up! The Practical Guidance and Law360 Podcasts Resource Kit features interviews with industry-leading attorneys on cutting edge issues in the law: NFTs, Cannabis, COVID-19, and more.


Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+